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community were not different from cluster sizes 
of the drug-resistant isolates, suggesting that the 
drug-resistant isolates are transmitted aseasily as 
the drug-susceptible isolates. In addition, the 
well-documented spread of the multidrug-resist- 
ant New York strain W is further evidence for 
transmissibility (as a virulence measure) of mul- 
tidrug-resistant tuberculosis (7). Our data from 
South Africa and the New York study demonstrate 
transmissibility of highly resistant strains and 
these strains have the ability to cause disease 
within a defined time interval. This may be inter- 
preted as a strong indicator of strain virulence, 
where virulence is defined as the ability to be 
transmitted and cause disease. Thus, we believe 
that resistance to high concentrations of isoni- 
azid does not (in general) imply lower strain viru- 
lence in the human as a function of impaired cat- 
alase activity. Virulence in these strains may be 
compensated for by the upregulation ofaddition- 
al virulence factors. Transmission of these resist- 
ant strains may create alarge reservoir of individ- 
uals infected by resistant strains, who in the near 
future could develop multidrug-resistant disease. 
Therefore, an increased understanding of the mo- 
lecular mechanisms a sociated with mycobacteri- 
al virulence in the human and efficient procedures 
for the quick diagnosis of drug resistance in My- 
cobacterium tuberculosis are important for preven- 
tion of transmission of these highly pathogenic 
strains. 
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Detection of Mycobacterium avium- 
intracellulare in the Blood of HIV-Infected 
Patients by a Commercial Polymerase Chain 
Reaction Kit 
In North America and Europe, disseminated in- 
fections with mycobacteria other than tuberculo- 
sis occur frequently inthe late stages of AIDS (1). 
In a prospective study of patients with positive my- 
cobacterial blood cultures in Switzerland, Myco- 
bacterium genavense was responsible for 12.8% of 
the infections (2), and Mycobacterium avium ac- 
counted for 82%. 
Until recently, the only method available to diag- 
nose these infections was culture in liquid medi- 
um (Bactec; Becton Dickinson, USA). Such cul- 
tures require a long incubation time (up to 14 
weeks) to become positive, which delays diagno- 
sis and treatment. Amplification methods uch as 
the polymerase chain reaction (PCR) applied di- 
rectly to blood specimens may accelerate diagno- 
sis. The few studies that have attempted todetect 
mycobacteria directly in blood have used nested 
PCR methods to increase sensitivity (3-5). How- 
ever, PCR performed on blood presents particu- 
lar methodologic problems because of the neces- 
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Table 1: Detection of Mycobacterium avium, Mycobacterium intracellulare, and Mycobacterium tuberculosis in blood from 
HIV-infected patients by the Amplicor PCR test and culture.* 
Culture positive Culture negative PCR 
M. aviurn M. intracellulare M. tuberculosis M. avium, M. intracellulare Sensitivity Specificity 
(n = 32) (n = 1 a) (n = 6) and M. tuberculosis (%) (%) 
(n = 162 b) 
PCR positive 14 0 1 0 
PCR negative 18 1 5 162 
42 c 100 c 
*The positive culture specimens were hybridized with the M.avium, M. intracellulare, and M. tuberculosis probes according to their identifi- 
cation by biochemical tests. The negative culture specimens were final hybridized with the M. avium probe. 
a Also positive for M. avium. 
b Four blood cultures positive for M. genavense, 1 positive for M. haemophilum; 157 blood cultures negative. 
c Sensitivity and specificity calculated for M. avium/M, intracellulare Amplicor test (values of the M. tuberculosis-positive cultures excluded). 
sity to eliminate inhibitors of the PCR, such as the 
heine compound, during preparation of the DNA 
sample (6). 
We report here the results of a retrospective 
study in which 43 of 200 Ficoll gradients from the 
blood of HIV-infected patients were positive for 
mycobacteria by culture in Bactec liquid medium. 
Samples were analyzed by a commercial PCR kit 
(Amplicor MAI; Roche Molecular Systems, Swit- 
zerland) that uses a simple PCR method to target 
the first variable region of the 16S rRNA gene. 
When used previously for the detection of Myco- 
bacterium tuberculosis complex in respiratory 
specimens, this PCR method had an overall sen- 
sitivity of approximately 70% and a specificity ex- 
ceeding 98% (7, 8). 
Blood samples were collected from patients in our 
hospital during a two-year period. Five ml of 
whole blood was cultured in Bactec 13A medium, 
and 5 ml was used to isolate the polynuclear and 
mononuclear blood cells in Ficoll/Hypaque solu- 
tion. These Ficoll samples were frozen and then 
analyzed in batches using the Amplicor MAI PCR 
assay according to the standard protocol provid- 
ed by the manufacturer. Briefly, the samples were 
prepared by washing the sample pellet three 
times with mycobacteria blood wash solution, 
lysing mycobacteria with mycobacteria blood 
lysis reagent and incubating at 60 ~ for 45 min, 
and adding a neutralization reagent to provide the 
magnesium necessary for amplification. The am- 
plification target is a 582 bp of the mycobacterial 
16S rRNA gene, and the amplicons are detected 
using a probe specific for Mycobacterium avium 
or Mycobacterium intracellulare. 
Of the 157 negative blood cultures, 43 were ob- 
tained from patients harboring mycobacteria n
other specimens such as sputum, bronchoalveolar 
lavage fluid, or biopsies; 17 negative blood cultures 
were contaminated by bacteria other than myco- 
bacteria. Of the 43 positive blood cultures, 31 were 
positive for Mycobacterium avium, one was 
mixed ( Mycobacterium avium and Mycobacterium 
intracellulare), four were positive for Mycobacte- 
rium genavense, six were positive for Mycobacte- 
rium tuberculosis, and one was positive for Myco- 
bacterium haemophilum. The six cultures positive 
for Mycobacterium tuberculosis were amplified by 
the Amplicor test, and the PCR products were hy- 
bridized with the Mycobacterium tuberculosis 
complex probe available in a commercial respir- 
atory kit (Amplicor M. tuberculosis complex; 
Roche Diagnostic System, Switzerland). 
The results of PCR compared with the results of 
Bactec culture, which is considered the gold stan- 
dard, are presented in Table 1. The sensitivity of 
the Amplicor Mycobacterium avium/Mycobacteri- 
um intracellulare t st on blood specimens was low 
(42%), whereas the specificity was excellent 
(100 %). Another technique to extract DNA from 
blood (QIAamp blood kit; Qiagen, Switzerland) 
was also performed, but no additional mycobac- 
teria-positive sample was detected by PCR. The 
weak sensitivity was not due to PCR inhibition, 
since an internal control was successfully co- 
amplified in each sample tested. The only blood 
sample positive for Mycobacterium avium and My- 
cobacterium intracellulare was tested by hybridi- 
zation with the Mycobacterium avium and the 
Mycobacterium intracellulare probes. These two 
hybridization results were negative. The amplifi- 
cation products of the six blood cultures positive 
for Mycobacterium tuberculosis were hybridized 
with the Mycobacterium tuberculosis complex 
probe supplied by the manufacturer (9). Only one 
blood culture was positive by PCR. 
The PCR results for Mycobacterium avium did not 
correlate with the time to positivity in the Bactec 
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system. The mean Bactec detection time was 16 
days and 14 days for positive and negative PCR 
results, respectively (p > 0.2). The time to positiv- 
ity in Bactec is correlated with the inoculum. 
Therefore, the lack of correlation we observed sug- 
gests that a low concentration of mycobacteria in 
the samples is not the only explanation for PCR 
negativity. This result differs from results with the 
Amplicor kit for respiratory specimens, in which 
sensitivity is higher for samples that are positive 
by microscopy. It also differs from an internal 
study conducted by Roche Diagnostic Systems (V. 
Tevere, Benchmark, Journal of Amplicor PCR Di- 
agnostics 1996, 3:6), which compared Amplicor 
MAI to quantitative culture to determine the de- 
tection limit of the test. Depending on the patho- 
gen load, a range of sensitivities was observed: 
36.4% when < 1 cfu/ml was tested; 66.7% with 
1-100 cfu/ml; and 100% with > 100 cfu/ml. 
In our study no correlation was seen between the 
PCR results and the clinical characteristics of the 
patients (CD4+ cell counts, levels of p24 antigen 
and 132 microglobulin, presence of antimycobac- 
terial treatment). For the same patient during the 
same period of hospitalization, some blood spec- 
imens were clearly positive by PCR, while others 
were devoid of positive signals. Our results are in 
accordance with those of Schneider et al. (36th 
ICAAC, 1996, Abstract no. 1165), who found the 
sensitivity of the Amplicor test to be 50% and the 
specificity 98 %. 
In our opinion the MAI Amplicor test is not sen- 
sitive enough to be used prospectively to detect 
Mycobacteriurn avium or Mycobacteriurn i tracel- 
lulare directly in the blood samples of all HIV- 
infected patients. The development of a nested 
PCR, along with improved methods for DNA 
preparation, may be essential to detect mycobac- 
terial DNA in more culture-positive blood samples. 
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Edwardsiella tarda Septicemia with Ceilulitis 
in a Patient with AIDS 
A 39-year-old woman was admitted to hospital in 
August 1994 with fever, rigors and confusion. She 
was known to be HIV-positive since 1990, and at 
the time of admission had a CD4+ cell count of 
6/mm 3. She had a history of pulmonary tubercu- 
losis in 1990, cerebral toxoplasmosis in 1991, 
cryptococcal meningitis in 1993, sclerosing cholan- 
gitis since 1994 and chronic hepatitis B (HBsAg 
positive, HBV DNA negative). A venous access 
device was implanted in September 1993 for ad- 
ministration of prolonged i.v. amphotericin B 
treatment, but removed in March 1994 due to cen- 
